Ajanta Pharma Limited (NSE: AJANTPHARM | BSE: 532331)
Source: Ajanta Pharma Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Ajanta Pharma Limited is a specialty pharmaceutical formulation company with a global presence across Branded Generics in India, Asia, and Africa; US Generics in the United States; and an Institutional Antimalarial business in Africa. The company operates a well-diversified business model driven by specialty-focused chronic therapies, a first-to-market product strategy, and a strong front-end commercial execution capability.
- India Branded Business: Ranked 24th in the Indian Pharmaceutical Market (IPM) as per IQVIA MAT March 2026 (improving from 26th rank). Outperformed IPM growth by 300 basis points, driven by 26 new product launches (5 first-to-market). Over 65% of domestic revenue originates from chronic therapeutic categories. Total domestic field force stands at ~3,750 Medical Representatives. Top 10 domestic brands contribute 53% of India sales.
- Emerging Markets (Asia & Africa): Spans 12 countries in Asia (Middle East, Southeast Asia, Central Asia) and 21 countries in Africa. Supported by a dedicated international field force of 2,250+ MRs (with 250+ MRs added in FY 2026). During FY 2026, 15 new products were launched in Asia and 8 in Africa.
- US Generics Business: Built on a selective portfolio play focusing on complex generics and niche filings. The portfolio features 49 Active ANDAs (excluding 6 tentative approvals), 19 ANDAs pending US FDA approval, and 49 commercialized products on shelf. During FY 2026, Ajanta filed 5 ANDAs, received 4 final approvals, and launched 3 new products. Target ANDA filings for FY 2027 are set at 8 to 12.
- Africa Institutional Business: Supplies WHO-prequalified antimalarial drugs (Artemether & Lumefantrine combination) through multilateral aid agencies and sponsors. Over 1 Billion patient treatments have been delivered through this program to date.
📋 Quick Facts / Company Snapshot: Ajanta Pharma Limited (NSE: AJANTPHARM | BSE: 532331)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Ajanta Pharma Limited |
| Corporate Identity Number (CIN) | L24230MH1979PLC022059 |
| ISIN | INE031B01049 |
| Stock Exchange Listing | BSE: 532331 | NSE: AJANTPHARM |
| Date of Incorporation | December 31, 1979 |
| Founders / Key Founding Figures | Mannalal B. Agrawal (Chairman) & Madhusudan B. Agrawal (Vice Chairman) |
| Registered Office & Corporate HQ | Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai – 400 093, Maharashtra, India |
| Telephone & Investor Email | Tel: +91 22 6060 9000 | Email: investorgrievance@ajantapharma.com / corpcom@ajantapharma.com |
| Managing Director | Yogesh M. Agrawal |
| Joint Managing Director | Rajesh M. Agrawal |
| Chief Financial Officer (CFO) | Arvind K. Agrawal |
| Company Secretary & Compliance Officer | Gaurang C. Shah (Sr. VP – Legal & Company Secretary) |
| Promoter & Holding Group | Agrawal Family (Agrawal Trusts, Gabs Investments Private Limited & Ganga Exports) |
| Industry / Sector Classification | Pharmaceutical Formulations / Specialty Pharmaceuticals (NIC Code: 210002) |
| Total Workforce & Employee Metrics | 13,000+ Ajantaites globally (Standalone: 10,404 permanent/other employees, 2,802 workers; Employee turnover rate: 18%) |
| Manufacturing Facilities Count | 7 state-of-the-art formulation facilities in India (Paithan, Chikalthana, Chitegaon, Waluj, Dahej, Guwahati, Pithampur) |
| Credit Ratings & Rating Agency | CARE Ratings: CARE AA+ (Long-Term Bank Facilities, Stable Outlook) | CARE A1+ (Short-Term Facilities) |
| Statutory Auditors | M/s B S R & Co. LLP, Chartered Accountants |
| Secretarial & Cost Auditors | Secretarial: M/s D.G. Prajapati & Associates | Cost: M/s RA & Co. |
| Registrar & Share Transfer Agent (RTA) | MUFG Intime India Private Limited (formerly Link Intime India Private Limited) |
🏢 The Corporate Identity: Ajanta Pharma Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Ajanta Pharma Limited is a specialty pharmaceutical formulation company with a global presence across Branded Generics in India, Asia, and Africa; US Generics in the United States; and an Institutional Antimalarial business in Africa. The company operates a well-diversified business model driven by specialty-focused chronic therapies, a first-to-market product strategy, and a strong front-end commercial execution capability. In FY 2025-26, Ajanta Pharma surpassed the landmark ₹ 5,000 Crores revenue milestone, reaching ₹ 5,452.86 Crores in Consolidated Revenue from Operations, while Net Profit crossed ₹ 1,000 Crores to stand at ₹ 1,056.00 Crores.
The core structural advantage of Ajanta Pharma lies in its geographic and therapeutic diversification, which protects the business from isolated macroeconomic or regulatory headwinds. Branded Generics represent the backbone of the organization, contributing 68% of overall sales in FY 2026. The company focuses heavily on high-margin chronic and specialist therapeutic segments such as Cardiology, Ophthalmology, Dermatology, and Pain Management, where nearly 50% of its 600+ commercialized products hold first-to-market status in their respective operating markets.
- Revenue Scale: Consolidated Revenue from Operations expanded 17% YoY to ₹ 5,452.86 Crores in FY 2025-26 compared to ₹ 4,648.10 Crores in FY 2024-25.
- Profitability Milestone: Consolidated Profit After Tax (PAT) crossed ₹ 1,000 Crores for the first time, expanding 15% YoY to ₹ 1,056.00 Crores.
- Adjusted EBITDA Margin: Adjusted EBITDA (after removing mark-to-market forex losses) reached ₹ 1,498.00 Crores, delivering a strong 27% operating margin.
- Export Focus: International markets remain the key growth engine, generating 69% (₹ 3,798.81 Crores) of consolidated turnover, while the India domestic business contributes 30% (₹ 1,653.85 Crores).
The Founders, Promoters & Their Legacy
Ajanta Pharma was founded under the stewardship of Mr. Mannalal B. Agrawal (Chairman) and Mr. Madhusudan B. Agrawal (Vice Chairman), who built the organization from a modest formulation entity into a multinational specialty pharmaceutical company. Over four decades, the promoter family established a governance architecture centered on quality without compromise, margin discipline, and prudent capital allocation. Today, executive leadership is spearheaded by Managing Director Mr. Yogesh M. Agrawal and Joint Managing Director Mr. Rajesh M. Agrawal.
The promoter and promoter group hold a 66.25% equity stake in the company as of March 31, 2026. The shareholding is primarily structured through family trusts (Yogesh Agrawal Trust, Rajesh Agrawal Trust, Ravi Agrawal Trust, Aayush Agrawal Trust), corporate entities (Gabs Investments Private Limited), and partnership firms (Ganga Exports), ensuring long-term stability and strategic alignment with minority shareholders.
The Journey: Corporate History & Key Milestones
Incorporated on December 31, 1979, Ajanta Pharma gradually evolved from manufacturing standard generic drugs to developing complex formulations and specialized drug delivery systems. Key historical milestones include:
- 1979–1990s: Establishment of initial manufacturing infrastructure in Maharashtra and building early brand equity in domestic specialty formulation markets.
- 2000s: Expansion into emerging markets across Southeast Asia, Central Asia, and Africa with customized branded generic portfolios; pioneer entry into WHO-prequalified antimalarial formulations.
- 2010s: Strategic entry into the highly regulated US Generics market through targeted ANDA filings; commissioning of advanced US FDA-compliant manufacturing assets at Dahej (Gujarat) and Guwahati (Assam).
- FY 2021–FY 2025: Aggressive front-end expansion, expanding total Medical Representatives (MRs) to over 6,000 globally; introduction of new domestic divisions including Gynaecology and Nephrology.
- FY 2025-26: Milestone achievement of crossing ₹ 5,000 Crores in Consolidated Revenue and ₹ 1,000 Crores in Net Profit; US business scale-up to ₹ 1,557 Crores (+49% YoY); receipt of Cencora Manufacturer Partner of the Year and 5th DIANA Award.
The Corporate Umbrella & Group Structure
Ajanta Pharma Limited functions as the parent operating company in India and operates through five wholly-owned overseas subsidiaries established in key international jurisdictions:
- Ajanta Pharma USA Inc. (USA): Material operating subsidiary overseeing commercialization, distribution, and regulatory interactions for the US Generics business. Recorded turnover of ₹ 1,505.74 Crores and PAT of ₹ 76.53 Crores in FY 2026.
- Ajanta Pharma Philippines Inc. (Philippines): Commercial arm managing branded generics marketing across the Philippines. Recorded turnover of ₹ 292.72 Crores and PAT of ₹ 9.50 Crores in FY 2026.
- Ajanta Pharma (Mauritius) Limited (Mauritius): Holds commercial operations and investment holdings for select African regional markets. Recorded turnover of ₹ 150.89 Crores and PAT of ₹ 7.59 Crores in FY 2026.
- Ajanta Pharma Nigeria Limited (Nigeria): Formed to support local distribution and registration in West Africa.
- Ajanta Pharma Ireland Limited (Ireland): Incorporated on December 19, 2025, as a wholly-owned European subsidiary to facilitate future international structure and regulatory registrations.
⚙️ The Business Engine: Ajanta Pharma Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Ajanta Pharma operates under a single primary reporting segment: Pharmaceutical Formulations. However, management tracks and reviews commercial performance across five distinct geographic and customer business verticals:
| Business Vertical | FY 2025-26 Revenue (₹ Cr) | FY 2024-25 Revenue (₹ Cr) | % Share of Total Revenue | Latest YoY (%) |
|---|---|---|---|---|
| Branded Generics – India | 1,654.00 | 1,452.00 | 30.3% | +13.91% |
| Branded Generics – Asia | 1,175.00 | 1,191.00 | 21.5% | -1.34% |
| Branded Generics – Africa | 861.00 | 750.00 | 15.8% | +14.80% |
| Total Branded Generics | 3,690.00 | 3,394.00 | 67.7% | +8.72% |
| US Generics | 1,557.00 | 1,047.00 | 28.6% | +48.71% |
| Africa Institutional (Antimalarial) | 160.00 | 147.00 | 2.9% | +8.84% |
| Total Consolidated Revenue | 5,453.00 | 4,648.00 | 100.0% | +17.32% |
The Product & Service Catalog (with Operational KPIs & Sourcing)
Ajanta Pharma’s portfolio consists of over 600 commercialized formulation products across oral solids, liquids, eye drops, creams, gels, and injectable dosage forms. Operational highlights across business verticals include:
- India Branded Business: Ranked 24th in the Indian Pharmaceutical Market (IPM) as per IQVIA MAT March 2026 (improving from 26th rank). Outperformed IPM growth by 300 basis points, driven by 26 new product launches (5 first-to-market). Over 65% of domestic revenue originates from chronic therapeutic categories. Total domestic field force stands at ~3,750 Medical Representatives. Top 10 domestic brands contribute 53% of India sales.
- Emerging Markets (Asia & Africa): Spans 12 countries in Asia (Middle East, Southeast Asia, Central Asia) and 21 countries in Africa. Supported by a dedicated international field force of 2,250+ MRs (with 250+ MRs added in FY 2026). During FY 2026, 15 new products were launched in Asia and 8 in Africa.
- US Generics Business: Built on a selective portfolio play focusing on complex generics and niche filings. The portfolio features 49 Active ANDAs (excluding 6 tentative approvals), 19 ANDAs pending US FDA approval, and 49 commercialized products on shelf. During FY 2026, Ajanta filed 5 ANDAs, received 4 final approvals, and launched 3 new products. Target ANDA filings for FY 2027 are set at 8 to 12.
- Africa Institutional Business: Supplies WHO-prequalified antimalarial drugs (Artemether & Lumefantrine combination) through multilateral aid agencies and sponsors. Over 1 Billion patient treatments have been delivered through this program to date.
- Customer Concentration (Ind AS 108): The company has 1 single external customer in the US Generics business that accounts for more than 10% of consolidated revenue, contributing ₹ 730.00 Crores (13.4% of total turnover) in FY 2026 compared to ₹ 621.00 Crores in FY 2025.
- Sourcing Split: Raw material consumption stands at ₹ 916.51 Crores in FY 2026. The company maintains active dual-sourcing strategies for key Active Pharmaceutical Ingredients (APIs) to mitigate supply chain concentration risks.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Molecule Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Atorvastatin + Clopidogrel Capsules | Cardiology (Branded Generics) | India & Emerging Markets; fixed-dose cardiovascular therapy for dyslipidemia and clot prevention. |
| Cilnidipine / Valsartan + Amlodipine | Cardiology (Branded Generics) | India, Asia & Africa; leading anti-hypertensive franchises with high physician mindshare. |
| Moxifloxacin Eye Drops / Ripasudil Eye Drops | Ophthalmology (Branded Generics) | India Rank #2 in Ophthalmology; advanced anti-infective and glaucoma treatment formulations. |
| Brinzolamide & Timolol Ophthalmic Suspension | Ophthalmology (Branded Generics / US) | US Generics & India; combination therapy for elevated intraocular pressure. |
| Dapagliflozin / Empagliflozin Tablets | Chronic / Diabetology (Branded Generics) | India & Asia; SGLT2 inhibitor portfolio targeting Type-2 diabetes and heart failure management. |
| Pimecrolimus Cream / Mometasone Furoate | Dermatology (Branded Generics) | India (Rank #13 in Derma) & Emerging Markets; topical anti-inflammatory and eczema care. |
| Artemether & Lumefantrine Tablets | Antimalarial (Africa Institutional) | Sub-Saharan Africa; 1st WHO-prequalified generic antimalarial for public health procurement programs. |
Mapping the Domestic & Global Reach (India vs. Exports)
| Geographic Region | FY 2025-26 Revenue (₹ Cr) | FY 2024-25 Revenue (₹ Cr) | % Share of Total Revenue | Latest YoY (%) |
|---|---|---|---|---|
| Domestic (India) | 1,653.85 | 1,452.49 | 30.3% | +13.86% |
| International / Exports | 3,799.01 | 3,195.61 | 69.7% | +18.88% |
| Total Revenue from Operations | 5,452.86 | 4,648.10 | 100.0% | +17.31% |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
Ajanta Pharma operates 7 state-of-the-art formulation manufacturing facilities in India, supplemented by specialized corporate and research centers:
- Paithan Facility (Aurangabad, Maharashtra): B-4, B-5, B-6, MIDC Industrial Area. Multi-dosage facility producing tablets, capsules, and oral liquids; compliant with WHO-cGMP. Features newly commissioned biomass boiler systems.
- Chikalthana Facility (Aurangabad, Maharashtra): 31-O, MIDC Industrial Area. Formulation manufacturing unit catering to domestic and emerging international markets.
- Chitegaon Facility (Aurangabad, Maharashtra): Gut No. 11/12/14/15, Chitegaon, Paithan Road. Specialized manufacturing plant for solid oral dosage forms.
- Waluj Facility (Aurangabad, Maharashtra): Gut No. 378, Plot No. 8. Formulation manufacturing asset.
- Dahej Facility (SEZ, Gujarat): Plot No. Z-103/A, Dahej SEZ – Part II, Dist. Bharuch. Advanced, US FDA-approved facility dedicated to high-volume oral solids for regulated markets. Equipped with high-capacity dehumidifiers and magnetic levitation chillers.
- Guwahati Facility (Kamrup, Assam): Mirza Palashbari Road, Mouza Chayani. Modern formulation plant awarded Gold Medal at the National Awards for Manufacturing Competitiveness (NAMC). Features automated shrink-wrapping and zero-liquid discharge systems.
- Pithampur Facility (Dhar, Madhya Pradesh): Plot No. M-55, 56, 57 ISEZ Phase-II. Multi-building complex featuring oral solid block, liquid plant, and sterile production lines. Recipient of the Environmental Excellence Award from the Government of Madhya Pradesh.
- Ajanta Research Centre (ARC, Mumbai): State-of-the-art analytical, XRD, LC-MS/MS, and formulation development laboratories employing over 850 scientists.
- Corporate HQ & Training Center: Ajanta Tower, 54-A, M Vasanji Road, Chakala, Andheri (E), Mumbai. Newly acquired and operational corporate facility housing executive functions and the ‘Ajanta Academy’ digital learning center.
📊 The Financial Health: Ajanta Pharma Financial Statements Simplified
Multi-Year Financial Highlights (₹ in Crores)
| Financial Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | Latest YoY (%) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 5,452.86 | 4,648.10 | 4,209.00 | 3,743.00 | 3,341.00 | +17.31% |
| Adjusted EBITDA | 1,498.00 | 1,268.00 | 1,172.00 | 802.00 | 929.00 | +18.14% |
| Adjusted EBITDA Margin (%) | 27.5% | 27.3% | 27.8% | 21.4% | 27.8% | – |
| Profit Before Tax (PBT) | 1,377.65 | 1,189.16 | 1,080.00 | 770.00 | 970.00 | +15.85% |
| Profit After Tax (PAT) | 1,056.00 | 920.39 | 816.00 | 588.00 | 713.00 | +14.73% |
| PAT Margin (%) | 19.4% | 19.8% | 19.4% | 15.7% | 21.3% | – |
| Basic EPS (₹) | 84.53 | 73.56 | 65.00 | 46.00 | 55.00 | +14.91% |
| Book Value Per Share (₹) | 362.00 | 303.00 | 282.00 | 264.00 | 252.00 | +19.47% |
| Return on Capital Employed (RoCE %) | 25.78% | 27.75% | 32.0% | 25.0% | 33.0% | – |
| Return on Equity (ROE %) | 23.33% | 24.28% | 23.0% | 18.0% | 23.0% | – |
| Cash Flow from Operations (CFO) | 525.00 | 1,157.00 | 792.00 | 523.00 | 562.00 | -54.62% |
| Total Capital Payout (Dividend + Buyback) | 350.00 | 701.00 | 642.00 | 350.00 | 436.00 | -50.07% |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
| Statement of Profit and Loss (₹ in Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 5,452.86 | 4,648.10 | +17.31% |
| Other Income | 172.07 | 94.50 | +82.08% |
| TOTAL INCOME | 5,624.93 | 4,742.60 | +18.60% |
| Cost of Materials Consumed | 916.51 | 846.60 | +8.26% |
| Purchase of Stock-in-Trade | 229.79 | 249.80 | -8.01% |
| Changes in Inventories of Finished Goods, WIP & Stock-in-Trade | 37.46 | (25.64) | N/M |
| Employee Benefits Expense | 1,291.15 | 1,089.69 | +18.49% |
| Finance Costs | 16.11 | 20.73 | -22.29% |
| Depreciation and Amortisation Expense | 173.14 | 144.11 | +20.14% |
| Other Expenses (including MTM Forex Hedge Loss of ₹ 103.04 Cr in FY26) | 1,583.12 | 1,228.15 | +28.90% |
| TOTAL EXPENSES | 4,247.28 | 3,553.44 | +19.53% |
| Profit Before Tax (PBT) | 1,377.65 | 1,189.16 | +15.85% |
| Current Tax Expense | 300.17 | 337.28 | -11.00% |
| Current Tax Expense for Earlier Years | (0.09) | (24.98) | -99.64% |
| Deferred Tax Expense / (Credit) | 21.57 | (43.53) | N/M |
| Total Tax Expense | 321.65 | 268.77 | +19.67% |
| PROFIT FOR THE YEAR (PAT) | 1,056.00 | 920.39 | +14.73% |
| Other Comprehensive Income / (Loss) (net of tax) | 29.08 | 1.85 | +1471.89% |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 1,085.08 | 922.24 | +17.66% |
| Basic Earnings Per Equity Share (₹) (Face Value ₹ 2/-) | 84.53 | 73.56 | +14.91% |
| Diluted Earnings Per Equity Share (₹) | 84.51 | 73.53 | +14.93% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Consolidated Balance Sheet (₹ in Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| Property, Plant and Equipment | 1,726.35 | 1,624.87 | +6.25% |
| Capital Work-in-Progress (CWIP) | 258.05 | 176.27 | +46.39% |
| Right-of-Use Assets | 99.02 | 90.63 | +9.26% |
| Other Intangible Assets | 41.58 | 46.52 | -10.62% |
| Non-Current Financial Investments | 28.50 | 25.24 | +12.92% |
| Other Non-Current Financial Assets | 7.99 | 9.25 | -13.62% |
| Deferred Tax Assets (net) | 188.59 | 186.43 | +1.16% |
| Income Tax Assets (net) | 7.56 | – | – |
| Other Non-Current Assets | 61.77 | 12.71 | +386.00% |
| Total Non-Current Assets | 2,419.41 | 2,171.92 | +11.39% |
| Inventories | 938.54 | 903.85 | +3.84% |
| Current Financial Investments | 559.85 | 438.71 | +27.61% |
| Trade Receivables | 1,853.88 | 1,182.74 | +56.74% |
| Cash and Cash Equivalents | 103.26 | 175.12 | -41.03% |
| Bank Balances other than Cash & Cash Equivalents | 1.51 | 1.12 | +34.82% |
| Current Loans | 1.68 | 2.54 | -33.86% |
| Other Current Financial Assets | 8.98 | 2.32 | +287.07% |
| Other Current Assets | 267.73 | 123.30 | +117.14% |
| Assets Classified as Held for Sale | – | 13.33 | – |
| Total Current Assets | 3,735.43 | 2,843.03 | +31.39% |
| TOTAL ASSETS | 6,154.84 | 5,014.95 | +22.73% |
| EQUITY AND LIABILITIES | |||
| Equity Share Capital | 25.07 | 25.07 | 0.00% |
| Other Equity | 4,502.02 | 3,765.22 | +19.57% |
| TOTAL EQUITY (NET WORTH) | 4,527.09 | 3,790.29 | +19.44% |
| Non-Current Lease Liabilities | 39.42 | 34.72 | +13.54% |
| Other Non-Current Financial Liabilities | 1.82 | 1.05 | +73.33% |
| Other Non-Current Liabilities | 1.67 | 2.00 | -16.50% |
| Non-Current Provisions | 51.15 | 80.27 | -36.28% |
| Deferred Tax Liabilities (net) | 117.94 | 110.52 | +6.71% |
| Total Non-Current Liabilities | 212.00 | 228.56 | -7.25% |
| Current Borrowings (Short-Term Working Capital & Vehicle Loans) | 211.99 | 2.59 | +8084.94% |
| Current Lease Liabilities | 8.76 | 10.11 | -13.35% |
| Trade Payables (MSME & Other Creditors) | 544.30 | 454.20 | +19.84% |
| Other Current Financial Liabilities | 495.82 | 374.20 | +32.50% |
| Other Current Liabilities | 119.00 | 91.12 | +30.60% |
| Current Provisions | 30.39 | 23.35 | +30.15% |
| Current Tax Liabilities (net) | 5.49 | 40.53 | -86.45% |
| Total Current Liabilities | 1,415.75 | 996.10 | +42.13% |
| TOTAL LIABILITIES | 1,627.75 | 1,224.66 | +32.91% |
| TOTAL EQUITY AND LIABILITIES | 6,154.84 | 5,014.95 | +22.73% |
Working Capital Cycle & Schedule III Statutory Ratios
Ajanta Pharma maintains tight operational control over its working capital cycle. Inventory efficiency improved during FY 2026, with holding days reducing to 63 days compared to 72 days in FY 2024-25. Trade payable days increased from 75 days in FY 2025 to 100 days in FY 2026, supporting cash flow management.
Trade receivable days expanded to 125 days in FY 2026 from 94 days in FY 2025 due to a strategic operational shift from factoring arrangements to low-cost working capital bank loans. This shift optimized interest efficiency while remaining neutral to the Statement of Profit and Loss, as interest costs were offset by corresponding treasury investment yields.
- Inventory Days: Improved to 63 days in FY 2026 (vs. 72 days in FY 2025) due to enhanced supply chain tracking.
- Trade Receivable Days: Expanded to 125 days in FY 2026 (vs. 94 days in FY 2025) following the transition from factoring to bank working capital facilities.
- Trade Payable Days: Increased to 100 days in FY 2026 (vs. 75 days in FY 2025), optimizing vendor credit cycles.
- Current Ratio: Stood at 2.64x in FY 2026 compared to 2.85x in FY 2025, reflecting strong liquidity headroom.
- Debt Service Coverage & Interest Coverage: Interest Coverage Ratio remained exceptionally strong, backed by low long-term funded debt and ₹ 1,377.65 Crores in PBT against ₹ 16.11 Crores in finance costs.
Cash Flow: Tracking the Money Movement
| Consolidated Statement of Cash Flows (₹ in Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated from Operating Activities (CFO) | 529.19 | 1,157.23 | -54.27% |
| Purchase of Property, Plant & Equipment and Intangibles (CapEx) | 365.16 | 317.92 | +14.86% |
| Proceeds from Sale of Property, Plant & Equipment | 5.41 | 1.14 | +374.56% |
| Purchase / Sale of Current Investments & Deposits (net) | (69.17) | (59.74) | +15.79% |
| Net Cash Used in Investing Activities | (428.92) | (376.52) | +13.92% |
| Proceeds from Issue of Equity Shares / Options | 0.01 | 0.01 | 0.00% |
| Net Proceeds / (Repayment) of Short-Term Borrowings | 209.40 | 1.10 | +18936.36% |
| Interest Paid | (12.80) | (17.31) | -26.05% |
| Payment of Lease Liabilities (including interest) | (14.80) | (14.89) | -0.60% |
| Dividends Paid to Equity Shareholders | (349.72) | (349.37) | +0.10% |
| Payment for Buyback of Equity Shares & Tax | – | (352.95) | – |
| Net Cash Used in Financing Activities | (167.92) | (733.41) | -77.10% |
| Net Increase / (Decrease) in Cash and Cash Equivalents | (67.65) | 47.30 | N/M |
| Cash & Cash Equivalents at End of Year | 103.26 | 175.12 | -41.03% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
Ajanta Pharma reinvests a significant portion of operating cash flows into capital assets and science-led R&D innovation to drive long-term organic growth. Key expenditure figures include:
- Capital Expenditure (CapEx) & CWIP: Total CapEx cash outflow in FY 2026 reached ₹ 365.16 Crores (gross additions to PPE of ₹ 264.38 Crores). Capital Work-in-Progress (CWIP) stood at ₹2.58 Crores, driven by the construction of a new oral solid block and liquid facility at Pithampur (Madhya Pradesh) and corporate office additions in Mumbai.
- Research & Development (R&D) Intensity: Total R&D expenditure (excluding capital assets) reached ₹ 251.58 Crores in FY 2026 (5% of revenue) compared to ₹ 224.41 Crores in FY 2025. Total R&D spend including capital expenditure stood at ₹2.60 Crores (4.77% of consolidated turnover). R&D operations employ over 850 scientists at the Ajanta Research Centre.
- Foreign Exchange Earnings & Outgo (Section 134(3)(m)):
- Foreign Exchange Actual Inflow (Earnings): ₹ 2,994.66 Crores (FY 2026) vs. ₹ 2,871.82 Crores (FY 2025).
- Foreign Exchange Actual Outflow (Used): ₹ 549.92 Crores (FY 2026) vs. ₹ 487.20 Crores (FY 2025).
- Net Foreign Exchange Earnings: ₹ 2,444.74 Crores.
👥 Power & Control: Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Mannalal B. Agrawal | Chairman | 00073828 | Promoter, Non-Executive Director |
| Mr. Madhusudan B. Agrawal | Vice Chairman | 00073872 | Promoter, Executive Director |
| Mr. Yogesh M. Agrawal | Managing Director | 00073673 | Promoter, Executive Director |
| Mr. Rajesh M. Agrawal | Joint Managing Director | 000302467 | Promoter, Executive Director |
| Mr. David Rasquinha | Lead Independent Director | 01172654 | Non-Executive, Independent Director |
| Mr. Rajesh S. Dalal | Independent Director | 03504969 | Non-Executive, Independent Director |
| Ms. Medha V. Joshi | Independent Director | 00328174 | Non-Executive, Independent Director |
| Ms. Simi M. Thapar | Independent Director | 10470498 | Non-Executive, Independent Director |
| Mr. Arvind K. Agrawal | Chief Financial Officer (CFO) | – | Key Managerial Personnel |
| Mr. Gaurang C. Shah | Sr. VP – Legal & Company Secretary | – | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
| Category of Shareholder | Number of Shares Held | % Shareholding |
|---|---|---|
| Promoter & Promoter Group | 8,27,72,954 | 66.25% |
| Institutional Investors (MFs, Banks, FIs) | 2,23,88,464 | 17.92% |
| NRIs / FPIs / Foreign Bodies / OCBs | 1,07,06,983 | 8.57% |
| Indian Public / Retail Shareholders | 81,58,300 | 6.53% |
| Others (AIFs, SWFs, Corporate Bodies, IEPF) | 9,08,923 | 0.73% |
| Total Issued Equity Capital | 12,49,35,624 | 100.00% |
- Promoter Shareholding Details: Major entities include Yogesh Agrawal Trust (14.47%), Rajesh Agrawal Trust (14.47%), Ravi Agrawal Trust (13.00%), Aayush Agrawal Trust (11.30%), and Gabs Investments Private Limited (10.08%).
- Dematerialization Level: 99.89% of total paid-up share capital is held in dematerialized form as of March 31, 2026. 100% of promoter holdings are dematerialized.
🗺️ The Corporate Family Tree: Subsidiaries, Ratings & Commitments
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
| Entity Name | Relationship | Country | % Shareholding | Turnover (₹ Cr) | Profit / (Loss) After Tax (₹ Cr) |
|---|---|---|---|---|---|
| Ajanta Pharma USA Inc. | Material Subsidiary | USA | 100% | 1,505.74 | 76.53 |
| Ajanta Pharma Philippines Inc. | Subsidiary | Philippines | 100% | 292.72 | 9.50 |
| Ajanta Pharma (Mauritius) Limited | Subsidiary | Mauritius | 100% | 150.89 | 7.59 |
| Ajanta Pharma Nigeria Limited | Subsidiary | Nigeria | 100% | 0.00 | (0.00) |
| Ajanta Pharma Ireland Limited | Subsidiary | Ireland | 100% | 0.00 | 0.00 |
| Turkmenderman Ajanta Pharma Ltd. | Joint Venture | Turkmenistan | 50% | – |
Credit Ratings, Treasury Investments & Contingent Liabilities
Ajanta Pharma maintains strong balance sheet flexibility, supported by high credit ratings and conservative debt management:
- Credit Ratings: CARE Ratings reaffirmed the company’s credit rating at CARE AA+ (Stable Outlook) for Long-Term Bank Facilities and CARE A1+ for Short-Term Facilities on August 25, 2025.
- Treasury & Investments: Non-current investments include ₹ 28.50 Crores in ABCD Technologies LLP (4.27% stake). Current investments of ₹ 559.85 Crores comprise mutual funds (₹ 125.35 Crores), Non-Convertible Debentures (₹ 318.45 Crores), Commercial Papers (₹ 111.47 Crores), and Alternative Investment Funds (₹ 4.58 Crores).
- Contingent Liabilities (Note 55): Disputed tax and regulatory claims not acknowledged as debt total ₹ 8.12 Crores (Excise, Service Tax, VAT & GST: ₹ 4.28 Crores; Income Tax: ₹ 3.23 Crores; Other legal matters: ₹ 0.61 Crores). Two ongoing patent litigations are pending with no liability expected.
- Capital Commitments: Estimated contracts remaining to be executed on capital account and not provided for stand at ₹ 296.09 Crores as of March 31, 2026. Pending export obligations under EPCG/Advance License schemes total ₹ 7.45 Crores.
- Income Tax Search Notice: In August 2025, the Income Tax Authorities conducted search operations at certain company premises. Pursuant to a notice under Section 158BC, Ajanta Pharma filed its block return on April 6, 2026, disclosing nil undisclosed income.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Ajanta Pharma’s sustainable competitive moat rests on four strategic pillars:
- First-to-Market Product Strategy: Nearly 50% of the company’s 600+ branded generic portfolio holds first-to-market advantage, allowing Ajanta to capture early market share and command premium brand positioning ahead of competitors.
- Front-End Distribution Density: A powerful field force of 6,000+ Medical Representatives (3,750 in India and 2,250 in Asia/Africa) provides deep prescriber coverage across specialists (Cardiologists, Ophthalmologists, Dermatologists) and healthcare institutions.
- Disciplined Selective US Play: Rather than competing in commoditized large-volume generics, Ajanta focuses on difficult-to-make complex oral solids and sterile formulations, maintaining reliable supply execution that earned the Cencora Manufacturer Partner of the Year Award.
- Quality Infrastructure & Green Energy Transition: Modern manufacturing facilities compliant with US FDA and WHO-cGMP standards. Renewable solar power currently satisfies 34% of energy requirements (16.6 MW total solar capacity), with a strategic target to reach 70% green power by FY 2027.
What Could Go Wrong? Key Challenges & Business Risks
Management actively tracks several strategic and operational risk factors:
- Geopolitical Disruptions & Currency Volatility: Recent conflicts in the Middle East impacted Asia business sales (-1% YoY) due to supply chain and shipping disruptions. Unfavorable currency depreciation in emerging markets can affect export realizations.
- Regulatory & Inspection Risks: Operating seven pharmaceutical formulation facilities exposes the company to evolving US FDA, CDSCO, and international WHO-cGMP compliance standards.
- Price Controls & Trade Generic Substitution: Expansion of the National List of Essential Medicines (NLEM) in India or increased trade generic substitution poses risks to domestic realization margins.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Looking ahead to FY 2027, Ajanta Pharma is positioned for accelerated growth as investments in field force expansion, new therapeutic divisions (Gynaecology and Nephrology), and manufacturing capacity enter their productive phase:
- India Specialty Expansion: Scale newly inducted Gynaecology and Nephrology teams while enhancing field force productivity across core Cardiology, Ophthalmology, and Dermatology franchises.
- US Pipeline Execution: Target 8 to 12 ANDA filings in FY 2027, leveraging the 19 ANDAs currently pending US FDA approval to maintain strong double-digit growth in regulated markets.
- Manufacturing Expansion: Complete ongoing capital projects, including the oral solid block and liquid facility at Pithampur, to support growing global volume demand without operational bottlenecks.
The Verdict: Strategic Outlook & Conclusion
With FY 2026 Revenue from Operations reaching ₹ 5,452.86 Crores, Profit After Tax crossing ₹ 1,056.00 Crores, and an Adjusted EBITDA margin of 27%, Ajanta Pharma has demonstrated robust financial resilience and commercial execution. Supported by a zero-net-debt balance sheet, strong return ratios (RoCE 33%, ROE 25%), and a well-diversified global presence, the company is well-positioned to deliver sustainable, profitable growth across all operating markets.
Frequently Asked Questions (FAQs) About Ajanta Pharma
Q1: What does Ajanta Pharma manufacture and what are its flagship brands?
Ajanta Pharma manufactures specialty pharmaceutical formulations across chronic and acute therapeutic segments, including Cardiology, Ophthalmology, Dermatology, Pain Management, Diabetology, Gynaecology, and Antimalarials. Flagship brand combinations include Atorvastatin + Clopidogrel, Cilnidipine, Dapagliflozin, Moxifloxacin Eye Drops, Ripasudil Eye Drops, Pimecrolimus Cream, and WHO-prequalified Artemether + Lumefantrine antimalarial tablets.
Q2: What were Ajanta Pharma’s revenue and net profit in FY 2025-26?
In FY 2025-26, Ajanta Pharma recorded Consolidated Revenue from Operations of ₹ 5,452.86 Crores (up 17% YoY from ₹ 4,648.10 Crores) and Consolidated Profit After Tax (PAT) of ₹ 1,056.00 Crores (up 15% YoY from ₹ 920.39 Crores).
Q3: Who are the promoters and key executives of Ajanta Pharma?
Ajanta Pharma was founded by Mr. Mannalal B. Agrawal (Chairman) and Mr. Madhusudan B. Agrawal (Vice Chairman). The executive leadership team is led by Mr. Yogesh M. Agrawal (Managing Director), Mr. Rajesh M. Agrawal (Joint Managing Director), and Mr. Arvind K. Agrawal (Chief Financial Officer). The promoter group holds a 66.25% equity stake as of March 31, 2026.
Q4: Where are Ajanta Pharma’s manufacturing facilities located and what is its export share?
Ajanta Pharma operates 7 formulation manufacturing plants in India located at Paithan, Chikalthana, Chitegaon, and Waluj in Maharashtra; Dahej in Gujarat; Guwahati in Assam; and Pithampur in Madhya Pradesh. International markets and exports contribute 69% (₹ 3,799.01 Crores) of total consolidated turnover across 33+ countries in Asia, Africa, and the United States.
Q5: What is Ajanta Pharma’s debt profile, credit rating, and net worth?
Ajanta Pharma maintains a net-cash position with total debt (working capital and vehicle loans) standing at ₹ 211.99 Crores against ₹ 663.11 Crores in cash, bank balances, and liquid current investments. The company’s Total Equity (Net Worth) expanded to ₹ 4,527.09 Crores as of March 31, 2026. CARE Ratings has assigned a long-term credit rating of CARE AA+ (Stable Outlook) and a short-term rating of CARE A1+.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.ajantapharma.com